rewirebio.iobenchmarks
Configuration

Zeng et al. 2026 classifier: End Motifs

Zeng et al. 2026 classifier: End Motifs, a configuration of Zeng et al. 2026 cfMeDIP-seq PCA classification workflow: PCs of 5' 4-mer end-motif frequencies from cfMeDIP-seq reads; algorithm chosen per feature set by nested cross-validation (not stated per row).

4 evaluations · 8 results

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

Model Capabilities & Hardware Requirements

Deployment facts recorded for Zeng et al. 2026 classifier: End Motifs. Fields the record does not carry are marked not recorded.

ParametersNot recorded
Minimum VRAMNot recorded
Inference LatencyNot recorded
Context WindowNot recorded
AccessNot recorded
LicenseNot recorded

Evaluations and results

4 evaluations · 8 results. Different protocols are not a single leaderboard.

Sorted by AUROC (cancer vs healthy, independent PE validation dataset, mean over 10 fold models) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.

Tested configurationProtocol and datasetAUROC (cancer vs healthy, independent PE validation dataset, mean over 10 fold models)AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models)AUROC (cancer vs healthy, primary SE dataset, mean over 10 fold models)AUROC (cancer vs healthy, SE 10% hold-out set, mean over 10 fold models)Sensitivity at 99% specificity (cancer vs healthy, independent PE validation dataset, mean over 10 fold models)Sensitivity at 99% specificity (cancer vs healthy, primary PE dataset, mean over 10 fold models)Sensitivity at 99% specificity (cancer vs healthy, primary SE dataset, mean over 10 fold models)Sensitivity at 99% specificity (cancer vs healthy, SE 10% hold-out set, mean over 10 fold models)
Zeng et al. 2026 classifier: End MotifsEvaluationZeng et al. 2026 independent PE validation dataset: cancer vs healthy, Zeng et al. 2026 independent paired-end validation dataset0.188Not reportedNot reportedNot reported0.0222Not reportedNot reportedNot reported
Zeng et al. 2026 classifier: End MotifsEvaluationZeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation, Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples)Not reported0.93Not reportedNot reportedNot reported0.826Not reportedNot reported
Zeng et al. 2026 classifier: End MotifsEvaluationZeng et al. 2026 primary SE dataset: cancer vs healthy, nested cross-validation, Zeng et al. 2026 primary single-end cfMeDIP-seq dataset (339 samples)Not reportedNot reported0.965Not reportedNot reportedNot reported0.905Not reported
Zeng et al. 2026 classifier: End MotifsEvaluationZeng et al. 2026 SE 10% hold-out set: cancer vs healthy, Zeng et al. 2026 single-end 10% hold-out set (39 samples)Not reportedNot reportedNot reported0.983Not reportedNot reportedNot reported0.893
All 8 result rows with coverage, uncertainty and sources
Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: Zeng et al. 2026 classifier: End MotifsProtocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation
Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples)
0.93 AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models)
unitless · higher

Uncertainty: SD 0.0519161667413912. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10).

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

End Motifs on pe primary cv (Zeng et al. 2026)

ctdnalit-20261011-zeng2026-protocol-pe-primary-cv

Aggregation: Not reported

A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4a, row 7 'End Motifs', column B 'mean_auc'
Configuration: Zeng et al. 2026 classifier: End MotifsProtocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation
Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples)
0.826 Sensitivity at 99% specificity (cancer vs healthy, primary PE dataset, mean over 10 fold models)
fraction · higher

Uncertainty: ± 0.136261133071318 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

End Motifs on pe primary cv (Zeng et al. 2026)

ctdnalit-20261011-zeng2026-protocol-pe-primary-cv

Aggregation: Not reported

A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4b, row 7 'End Motifs', column B 'mean_sens99'
Configuration: Zeng et al. 2026 classifier: End MotifsProtocol: Zeng et al. 2026 independent PE validation dataset: cancer vs healthy
Dataset: Zeng et al. 2026 independent paired-end validation dataset
0.188 AUROC (cancer vs healthy, independent PE validation dataset, mean over 10 fold models)
unitless · higher

Uncertainty: SD 0.0590546576842708. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10).

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

End Motifs on pe validation (Zeng et al. 2026)

ctdnalit-20261011-zeng2026-protocol-pe-validation

Aggregation: Not reported

A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4c, row 3 'End Motifs', column B 'mean_auc'
Configuration: Zeng et al. 2026 classifier: End MotifsProtocol: Zeng et al. 2026 independent PE validation dataset: cancer vs healthy
Dataset: Zeng et al. 2026 independent paired-end validation dataset
0.0222 Sensitivity at 99% specificity (cancer vs healthy, independent PE validation dataset, mean over 10 fold models)
fraction · higher

Uncertainty: ± 0.0104756560175785 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

End Motifs on pe validation (Zeng et al. 2026)

ctdnalit-20261011-zeng2026-protocol-pe-validation

Aggregation: Not reported

A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4d, row 11 'End Motifs', column B 'mean_sens99'
Configuration: Zeng et al. 2026 classifier: End MotifsProtocol: Zeng et al. 2026 primary SE dataset: cancer vs healthy, nested cross-validation
Dataset: Zeng et al. 2026 primary single-end cfMeDIP-seq dataset (339 samples)
0.965 AUROC (cancer vs healthy, primary SE dataset, mean over 10 fold models)
unitless · higher

Uncertainty: SD 0.033. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10).

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

End Motifs on se primary cv (Zeng et al. 2026)

ctdnalit-20261011-zeng2026-protocol-se-primary-cv

Aggregation: Not reported

A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4e, row 3 'End Motifs', column B 'mean_auc'
Configuration: Zeng et al. 2026 classifier: End MotifsProtocol: Zeng et al. 2026 primary SE dataset: cancer vs healthy, nested cross-validation
Dataset: Zeng et al. 2026 primary single-end cfMeDIP-seq dataset (339 samples)
0.905 Sensitivity at 99% specificity (cancer vs healthy, primary SE dataset, mean over 10 fold models)
fraction · higher

Uncertainty: ± 0.0765817288831197 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

End Motifs on se primary cv (Zeng et al. 2026)

ctdnalit-20261011-zeng2026-protocol-se-primary-cv

Aggregation: Not reported

A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4f, row 3 'End Motifs', column B 'mean_sens99'
Configuration: Zeng et al. 2026 classifier: End MotifsProtocol: Zeng et al. 2026 SE 10% hold-out set: cancer vs healthy
Dataset: Zeng et al. 2026 single-end 10% hold-out set (39 samples)
0.983 AUROC (cancer vs healthy, SE 10% hold-out set, mean over 10 fold models)
unitless · higher

Uncertainty: SD 0.005. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10).

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

End Motifs on se validation (Zeng et al. 2026)

ctdnalit-20261011-zeng2026-protocol-se-validation

Aggregation: Not reported

A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4g, row 3 'End Motifs', column B 'mean_auc'
Configuration: Zeng et al. 2026 classifier: End MotifsProtocol: Zeng et al. 2026 SE 10% hold-out set: cancer vs healthy
Dataset: Zeng et al. 2026 single-end 10% hold-out set (39 samples)
0.893 Sensitivity at 99% specificity (cancer vs healthy, SE 10% hold-out set, mean over 10 fold models)
fraction · higher

Uncertainty: ± 0.0344265186329548 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

End Motifs on se validation (Zeng et al. 2026)

ctdnalit-20261011-zeng2026-protocol-se-validation

Aggregation: Not reported

A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4h, row 3 'End Motifs', column B 'mean_sens99'

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Use this configuration

How it works, versions and access

Additional methodological details, versions and access terms have not yet been extracted into a structured profile for this configuration. Consult the linked sources and evaluation records below.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance

No evidence rows match these filters. Choose another scope or clear the search.

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

2 source records and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID ctdnalit-20261011-zeng2026-config-end-motifs.

Source locator: Source Data Fig. 4 row labels; Results P29-P33; Methods P59

Related records

How to cite

Zeng et al. 2026 classifier: End Motifs. Rewire biological model benchmark database, release 2026-11-21-c8bea25e5abb. https://benchmarks.rewirebio.io/database/configuration/ctdnalit-20261011-zeng2026-config-end-motifs/

Release 2026-11-21-c8bea25e5abb. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.

The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence

Suggest a correction